Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy.
Ontology highlight
ABSTRACT: Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One of the interesting targets for GB therapy is the histone deacetylase family (HDAC). Due to their pleiotropic effects on, e.g., DNA repair, cell proliferation, differentiation, apoptosis and cell cycle, HDAC inhibitors have gained a lot of attention in the last decade as anti-cancer agents. Despite their known underlying mechanism, their therapeutic activity is not well-defined. In this review, an extensive overview is given of the current status of HDAC inhibitors for GB therapy, followed by an overview of current HDAC-targeting radiopharmaceuticals. Imaging HDAC expression or activity could provide key insigh
SUBMITTER: Everix L
PROVIDER: S-EPMC9967489 | biostudies-literature | 2023 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA